Faculty & Research
Publications
Publications

Development of CAR-T Therapies: Case Histories of Significant Medical Advances

By: Amar Bhidé and Srikant M. Datar
  • Format:Print
  • | Language:English
  • | Pages:24
ShareBar

Abstract

In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works; 2) the foundational advances and discoveries; 3) development of CAR-T therapy; and 4) the situation in 2019.

Keywords

Immunotherapy; Health Care and Treatment; Innovation and Invention; Research and Development; Governing Rules, Regulations, and Reforms

Citation

Bhidé, Amar, and Srikant M. Datar. "Development of CAR-T Therapies: Case Histories of Significant Medical Advances." Harvard Business School Working Paper, No. 21-035, August 2020. (Revised May 2021.)

About The Author

Srikant M. Datar

More Publications

More from the Authors